Tetraphase Pharmaceuticals Inc (TTPH) Expected to Announce Quarterly Sales of $2.18 Million

Wall Street brokerages expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to post $2.18 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $750,000.00 and the highest estimate coming in at $3.60 million. Tetraphase Pharmaceuticals reported sales of $11.58 million during the same quarter last year, which indicates a negative year over year growth rate of 81.2%. The firm is expected to report its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full year sales of $10.05 million for the current fiscal year, with estimates ranging from $4.10 million to $16.57 million. For the next year, analysts expect that the company will post sales of $24.40 million, with estimates ranging from $10.50 million to $49.37 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.03. The company had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.93 million. Tetraphase Pharmaceuticals had a negative return on equity of 80.01% and a negative net margin of 383.19%.

Several research firms recently commented on TTPH. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. ValuEngine upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. Gabelli lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.40 price target for the company. in a research report on Friday, March 15th. SunTrust Banks dropped their price target on Tetraphase Pharmaceuticals to $4.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Finally, Piper Jaffray Companies dropped their price target on Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating for the company in a research report on Friday, March 15th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $4.08.

Several large investors have recently made changes to their positions in the business. Paloma Partners Management Co purchased a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter valued at approximately $33,000. Gamco Investors INC. ET AL boosted its position in shares of Tetraphase Pharmaceuticals by 42.9% during the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 15,000 shares during the period. SG Americas Securities LLC purchased a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter valued at approximately $69,000. Rhumbline Advisers boosted its position in shares of Tetraphase Pharmaceuticals by 40.6% during the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 21,089 shares during the period. Finally, State of Wisconsin Investment Board boosted its position in shares of Tetraphase Pharmaceuticals by 29.8% during the first quarter. State of Wisconsin Investment Board now owns 71,000 shares of the biopharmaceutical company’s stock valued at $95,000 after buying an additional 16,300 shares during the period. Institutional investors and hedge funds own 39.56% of the company’s stock.

TTPH traded down $0.04 on Thursday, hitting $0.78. The company had a trading volume of 366,100 shares, compared to its average volume of 608,891. The firm has a market cap of $43.25 million, a P/E ratio of -0.57 and a beta of 2.85. Tetraphase Pharmaceuticals has a 12-month low of $0.75 and a 12-month high of $4.49. The company has a current ratio of 7.28, a quick ratio of 7.10 and a debt-to-equity ratio of 0.53.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Further Reading: Penny Stocks, Risk and Reward Factors

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.